Drug profile · INN
aminosalicylic acid resin complex
REZIPAS
aminosalicylic acid resin complex (REZIPAS) is a dihydrofolate reductase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — aminosalicylic acid resin complex
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 0
- Data quality
- 0.84
Quick answer
aminosalicylic acid resin complex (REZIPAS) is a dihydrofolate reductase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dihydrofolate reductase inhibitor
Primary target: Dihydrofolate reductase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Related patents
Frequently asked questions
What is aminosalicylic acid resin complex?
aminosalicylic acid resin complex (REZIPAS) is a dihydrofolate reductase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for aminosalicylic acid resin complex?
REZIPAS is a marketed brand name for aminosalicylic acid resin complex. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of aminosalicylic acid resin complex?
aminosalicylic acid resin complex has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.